GLPwatch
Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
NCT02617654 · Completed
Last updated 2026-05-28This trial tested whether the drug liraglutide, compared to a placebo, affects insulin-producing cell function in adults with long-standing type 1 diabetes who still have some remaining insulin production.
What this study is testing ClinicalTrials.gov NCT02617654 ↗
Description as written by the study sponsor.
Recent studies show that many Type 1 diabetes patients have remaining endogenous insulin production, albeit at low levels. Finding means to increase this production would be of tremendous interest, since residual C-peptide concentrations \>0.1 nmol/l previously have been shown to markedly lower HbA1c, decrease blood glucose fluctuations and diminish the risk of ketoacidosis. It also substantially reduces the risks of severe hypoglycemic events and late complications. Liraglutide may through its incretin effect directly potentiate beta-cell function, but also holds the potential to be mitogenic for these cells. The hypothesis of the present trial is that treatment with liraglutide will not only have a direct effect on beta-cell function, which is more or less immediately observed, but also progressively improve C-peptide concentrations over time.
Treatments tested
- Liraglutide Drug
Treatment with liraglutide for 52 weeks
- Placebo for liraglutide Drug
Placebo for liraglutide. Treatment once daily for 52 weeks
| Main thing measured | The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production |
|---|---|
| Sponsor | Per-Ola Carlsson |
| Conditions studied | Type 1 Diabetes |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02617654 ↗